Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 May 15;99(10):2545–2553. doi: 10.1172/JCI119439

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

K S Lown 1, D G Bailey 1, R J Fontana 1, S K Janardan 1, C H Adair 1, L A Fortlage 1, M B Brown 1, W Guo 1, P B Watkins 1
PMCID: PMC508096  PMID: 9153299

Abstract

The increase in oral availability of felodipine and other commonly used medications when taken with grapefruit juice has been assumed to be due to inhibition of CYP3A4, a cytochrome P450 that is present in liver and intestine. To evaluate the effect of repeated grapefruit juice ingestion on CYP3A4 expression, 10 healthy men were given 8 oz of grapefruit juice three times a day for 6 d. Before and after receiving grapefruit juice, small bowel and colon mucosal biopsies were obtained endoscopically, oral felodipine kinetics were determined, and liver CYP3A4 activity was measured with the [14C N-methyl] erythromycin breath test in each subject. Grapefruit juice did not alter liver CYP3A4 activity, colon levels of CYP3A5, or small bowel concentrations of P-glycoprotein, villin, CYP1A1, and CYP2D6. In contrast, the concentration of CYP3A4 in small bowel epithelia (enterocytes) fell 62% (P = 0.0006) with no corresponding change in CYP3A4 mRNA levels. In addition, enterocyte concentrations of CYP3A4 measured before grapefruit juice consumption correlated with the increase in Cmax when felodipine was taken with either the 1st or the 16th glass of grapefruit juice relative to water (r = 0. 67, P = 0.043, and r = 0.71, P = 0.022, respectively). We conclude that a mechanism for the effect of grapefruit juice on oral felodipine kinetics is its selective downregulation of CYP3A4 in the small intestine.

Full Text

The Full Text of this article is available as a PDF (289.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahnoff M. Determination of felodipine in plasma by capillary gas chromatography with electron capture detection. J Pharm Biomed Anal. 1984;2(3-4):519–526. doi: 10.1016/0731-7085(84)80055-2. [DOI] [PubMed] [Google Scholar]
  2. Aoyama T., Yamano S., Waxman D. J., Lapenson D. P., Meyer U. A., Fischer V., Tyndale R., Inaba T., Kalow W., Gelboin H. V. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem. 1989 Jun 25;264(18):10388–10395. [PubMed] [Google Scholar]
  3. Bailey D. G., Arnold J. M., Bend J. R., Tran L. T., Spence J. D. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol. 1995 Aug;40(2):135–140. [PMC free article] [PubMed] [Google Scholar]
  4. Bailey D. G., Spence J. D., Munoz C., Arnold J. M. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991 Feb 2;337(8736):268–269. doi: 10.1016/0140-6736(91)90872-m. [DOI] [PubMed] [Google Scholar]
  5. Benton R. E., Honig P. K., Zamani K., Cantilena L. R., Woosley R. L. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther. 1996 Apr;59(4):383–388. doi: 10.1016/S0009-9236(96)90105-8. [DOI] [PubMed] [Google Scholar]
  6. Bonkovsky H. L., Hauri H. P., Marti U., Gasser R., Meyer U. A. Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. Gastroenterology. 1985 Feb;88(2):458–467. doi: 10.1016/0016-5085(85)90507-4. [DOI] [PubMed] [Google Scholar]
  7. Chen C. J., Chin J. E., Ueda K., Clark D. P., Pastan I., Gottesman M. M., Roninson I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986 Nov 7;47(3):381–389. doi: 10.1016/0092-8674(86)90595-7. [DOI] [PubMed] [Google Scholar]
  8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  9. Cribb A., Nuss C., Wang R. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Drug Metab Dispos. 1995 Jul;23(7):671–675. [PubMed] [Google Scholar]
  10. Ducharme M. P., Provenzano R., Dehoorne-Smith M., Edwards D. J. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol. 1993 Nov;36(5):457–459. doi: 10.1111/j.1365-2125.1993.tb00395.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ducharme M. P., Warbasse L. H., Edwards D. J. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995 May;57(5):485–491. doi: 10.1016/0009-9236(95)90032-2. [DOI] [PubMed] [Google Scholar]
  12. Edgar B., Regårdh C. G., Johnsson G., Johansson L., Lundborg P., Löfberg I., Rönn O. Felodipine kinetics in healthy men. Clin Pharmacol Ther. 1985 Aug;38(2):205–211. doi: 10.1038/clpt.1985.160. [DOI] [PubMed] [Google Scholar]
  13. Edwards D. J., Bellevue F. H., 3rd, Woster P. M. Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos. 1996 Dec;24(12):1287–1290. [PubMed] [Google Scholar]
  14. Fromm M. F., Busse D., Kroemer H. K., Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 1996 Oct;24(4):796–801. doi: 10.1002/hep.510240407. [DOI] [PubMed] [Google Scholar]
  15. Guengerich F. P., Brian W. R., Iwasaki M., Sari M. A., Bärnhielm C., Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991 Jun;34(6):1838–1844. doi: 10.1021/jm00110a012. [DOI] [PubMed] [Google Scholar]
  16. Guengerich F. P., Kim D. H. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis. 1990 Dec;11(12):2275–2279. doi: 10.1093/carcin/11.12.2275. [DOI] [PubMed] [Google Scholar]
  17. Guengerich F. P. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol. 1988 May;33(5):500–508. [PubMed] [Google Scholar]
  18. Hoensch H. P., Steinhardt H. J., Weiss G., Haug D., Maier A., Malchow H. Effects of semisynthetic diets on xenobiotic metabolizing enzyme activity and morphology of small intestinal mucosa in humans. Gastroenterology. 1984 Jun;86(6):1519–1530. [PubMed] [Google Scholar]
  19. Hostetler K. A., Wrighton S. A., Molowa D. T., Thomas P. E., Levin W., Guzelian P. S. Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Mol Pharmacol. 1989 Mar;35(3):279–285. [PubMed] [Google Scholar]
  20. Hsing S., Gatmaitan Z., Arias I. M. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology. 1992 Mar;102(3):879–885. doi: 10.1016/0016-5085(92)90173-v. [DOI] [PubMed] [Google Scholar]
  21. Kolars J. C., Awni W. M., Merion R. M., Watkins P. B. First-pass metabolism of cyclosporin by the gut. Lancet. 1991 Dec 14;338(8781):1488–1490. doi: 10.1016/0140-6736(91)92302-i. [DOI] [PubMed] [Google Scholar]
  22. Kolars J. C., Lown K. S., Schmiedlin-Ren P., Ghosh M., Fang C., Wrighton S. A., Merion R. M., Watkins P. B. CYP3A gene expression in human gut epithelium. Pharmacogenetics. 1994 Oct;4(5):247–259. doi: 10.1097/00008571-199410000-00003. [DOI] [PubMed] [Google Scholar]
  23. Kolars J. C., Schmiedlin-Ren P., Schuetz J. D., Fang C., Watkins P. B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992 Nov;90(5):1871–1878. doi: 10.1172/JCI116064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kupferschmidt H. H., Ha H. R., Ziegler W. H., Meier P. J., Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995 Jul;58(1):20–28. doi: 10.1016/0009-9236(95)90068-3. [DOI] [PubMed] [Google Scholar]
  25. Lown K. S., Kolars J. C., Thummel K. E., Barnett J. L., Kunze K. L., Wrighton S. A., Watkins P. B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994 Nov-Dec;22(6):947–955. [PubMed] [Google Scholar]
  26. Lown K., Kolars J., Turgeon K., Merion R., Wrighton S. A., Watkins P. B. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 1992 Mar;51(3):229–238. doi: 10.1038/clpt.1992.17. [DOI] [PubMed] [Google Scholar]
  27. Lundahl J., Regårdh C. G., Edgar B., Johnsson G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol. 1995;49(1-2):61–67. doi: 10.1007/BF00192360. [DOI] [PubMed] [Google Scholar]
  28. Menard R. H., Guenthner T. M., Kon H., Gillette J. R. Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7alpha-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450. J Biol Chem. 1979 Mar 10;254(5):1726–1733. [PubMed] [Google Scholar]
  29. Miniscalco A., Lundahl J., Regårdh C. G., Edgar B., Eriksson U. G. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther. 1992 Jun;261(3):1195–1199. [PubMed] [Google Scholar]
  30. Paine M. F., Shen D. D., Kunze K. L., Perkins J. D., Marsh C. L., McVicar J. P., Barr D. M., Gillies B. S., Thummel K. E. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996 Jul;60(1):14–24. doi: 10.1016/S0009-9236(96)90162-9. [DOI] [PubMed] [Google Scholar]
  31. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077–6080. [PubMed] [Google Scholar]
  32. Schmiedlin-Ren P., Benedict P. E., Dobbins W. O., 3rd, Ghosh M., Kolars J. C., Watkins P. B. Cultured adult rat jejunal explants as a model for studying regulation of CYP3A. Biochem Pharmacol. 1993 Sep 1;46(5):905–918. doi: 10.1016/0006-2952(93)90501-m. [DOI] [PubMed] [Google Scholar]
  33. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994 Jul;270(1):414–423. [PubMed] [Google Scholar]
  34. Smit J. J., Schinkel A. H., Mol C. A., Majoor D., Mooi W. J., Jongsma A. P., Lincke C. R., Borst P. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest. 1994 Nov;71(5):638–649. [PubMed] [Google Scholar]
  35. Tephly T. R., Black K. A., Green M. D., Coffman B. L., Dannan G. A., Guengerich F. P. Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins. Mol Pharmacol. 1986 Jan;29(1):81–87. [PubMed] [Google Scholar]
  36. Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735–7738. doi: 10.1073/pnas.84.21.7735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Tierney D. J., Haas A. L., Koop D. R. Degradation of cytochrome P450 2E1: selective loss after labilization of the enzyme. Arch Biochem Biophys. 1992 Feb 14;293(1):9–16. doi: 10.1016/0003-9861(92)90358-4. [DOI] [PubMed] [Google Scholar]
  38. Turgeon D. K., Leichtman A. B., Lown K. S., Normolle D. P., Deeb G. M., Merion R. M., Watkins P. B. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther. 1994 Sep;56(3):253–260. doi: 10.1038/clpt.1994.135. [DOI] [PubMed] [Google Scholar]
  39. Wacher V. J., Wu C. Y., Benet L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995 Jul;13(3):129–134. doi: 10.1002/mc.2940130302. [DOI] [PubMed] [Google Scholar]
  40. Wang S. X., Sutfin T. A., Bärnhielm C., Regårdh C. G. Contribution of the intestine to the first-pass metabolism of felodipine in the rat. J Pharmacol Exp Ther. 1989 Aug;250(2):632–636. [PubMed] [Google Scholar]
  41. Watkins P. B., Murray S. A., Winkelman L. G., Heuman D. M., Wrighton S. A., Guzelian P. S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest. 1989 Feb;83(2):688–697. doi: 10.1172/JCI113933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Watkins P. B., Wrighton S. A., Maurel P., Schuetz E. G., Mendez-Picon G., Parker G. A., Guzelian P. S. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6310–6314. doi: 10.1073/pnas.82.18.6310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Watkins P. B., Wrighton S. A., Schuetz E. G., Molowa D. T., Guzelian P. S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest. 1987 Oct;80(4):1029–1036. doi: 10.1172/JCI113156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Weber A., Jäger R., Börner A., Klinger G., Vollanth R., Matthey K., Balogh A. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception. 1996 Jan;53(1):41–47. doi: 10.1016/0010-7824(95)00252-9. [DOI] [PubMed] [Google Scholar]
  45. Wrighton S. A., Brian W. R., Sari M. A., Iwasaki M., Guengerich F. P., Raucy J. L., Molowa D. T., Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol. 1990 Aug;38(2):207–213. [PubMed] [Google Scholar]
  46. Wrighton S. A., Maurel P., Schuetz E. G., Watkins P. B., Young B., Guzelian P. S. Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry. 1985 Apr 23;24(9):2171–2178. doi: 10.1021/bi00330a010. [DOI] [PubMed] [Google Scholar]
  47. Wu C. Y., Benet L. Z., Hebert M. F., Gupta S. K., Rowland M., Gomez D. Y., Wacher V. J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995 Nov;58(5):492–497. doi: 10.1016/0009-9236(95)90168-X. [DOI] [PubMed] [Google Scholar]
  48. Yun C. H., Okerholm R. A., Guengerich F. P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos. 1993 May-Jun;21(3):403–409. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES